Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorUlu, Bahar Uncu
dc.contributor.authorUzay, Ant
dc.contributor.authorAkay, Olga Meltem
dc.contributor.authorBesisik, Sevgi
dc.contributor.authorYenerel, Mustafa Nuri
dc.contributor.authorCelik, Serhat
dc.contributor.authorKaynar, Leylagul
dc.contributor.authorYucel, Orhan Kemal
dc.contributor.authorDeveci, Burak
dc.contributor.authorSonmez, Mehmet
dc.contributor.authorMehtap, Ozgur
dc.contributor.authorBekoz, Huseyin Saffet
dc.contributor.authorSunu, Cenk
dc.contributor.authorSalim, Ozan
dc.contributor.authorUlas, Turgay
dc.contributor.authorKarti, Sami
dc.contributor.authorAltuntas, Fevzi
dc.contributor.authorFerhanoglu, Burhan
dc.contributor.authorTuglular, Tulin Firat
dc.date.accessioned2023-02-21T12:41:56Z
dc.date.available2023-02-21T12:41:56Z
dc.date.issued2023-01-01
dc.description.abstractPolatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m(2) on day 1, and bendamustine 90 mg/m(2) on days 1-2 of each cycle. Median age at Pola-BR initiation was 55 (19-84). The overall response rate was 47.9\%, including 32.4\% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3-4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile.
dc.description.issue1
dc.description.issueJAN
dc.description.pages133-140
dc.description.volume102
dc.identifier.doi10.1007/s00277-022-05052-x
dc.identifier.urihttps://hdl.handle.net/11443/2767
dc.identifier.urihttp://dx.doi.org/10.1007/s00277-022-05052-x
dc.identifier.wosWOS:000885401400002
dc.publisherSPRINGER
dc.relation.ispartofANNALS OF HEMATOLOGY
dc.subjectDiffuse large B-cell lymphoma
dc.subjectPolatuzumab vedotin
dc.subjectRefractory
dc.subjectRelapsed
dc.subjectRituximab
dc.subjectBendamustine
dc.titlePolatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
dc.typeArticle

Files

Collections